Creso Pharma


PharmaCielo Ltd.

CVE: PCLO


Canadian symbol: PCLO.V
US symbol: PCLOF

Currency in CAD

Valuation Measures

Market Cap (intraday) 5262.61M
Enterprise Value 3254.74M
Trailing P/E N/A
Forward P/E 14.95
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)108.09
Price/Book (mrq)6.47
Enterprise Value/Revenue 3104.85
Enterprise Value/EBITDA 7-7.17

Trading Information

Stock Price History

Beta (5Y Monthly) 3.71
52-Week Change 3165.22%
S&P500 52-Week Change 349.51%
52 Week High 32.9400
52 Week Low 30.4100
50-Day Moving Average 32.1337
200-Day Moving Average 31.5250

Share Statistics

Avg Vol (3 month) 3362.91k
Avg Vol (10 day) 3356.97k
Shares Outstanding 5139.73M
Implied Shares Outstanding 6N/A
Float 119.56M
% Held by Insiders 12.32%
% Held by Institutions 15.83%
Shares Short (Mar. 14, 2021) 41.6M
Short Ratio (Mar. 14, 2021) 45.32
Short % of Float (Mar. 14, 2021) 4N/A
Short % of Shares Outstanding (Mar. 14, 2021) 41.16%
Shares Short (prior month Feb. 11, 2021) 4645.46k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jan. 17, 2019
Ex-Dividend Date 4N/A
Last Split Factor 21:11
Last Split Date 3Jan. 17, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Sep. 29, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,517.30%

Management Effectiveness

Return on Assets (ttm)-48.53%
Return on Equity (ttm)-88.71%

Income Statement

Revenue (ttm)2.43M
Revenue Per Share (ttm)0.02
Quarterly Revenue Growth (yoy)-80.10%
Gross Profit (ttm)643.48k
EBITDA -35.54M
Net Income Avi to Common (ttm)-36.26M
Diluted EPS (ttm)-0.3450
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)3.33M
Total Cash Per Share (mrq)0.02
Total Debt (mrq)1.41M
Total Debt/Equity (mrq)4.20
Current Ratio (mrq)1.91
Book Value Per Share (mrq)0.28

Cash Flow Statement

Operating Cash Flow (ttm)-21.52M
Levered Free Cash Flow (ttm)-17.06M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
PCLO.V
PharmaCielo
2 weeks ago
PCLO.V
PharmaCielo
2 weeks ago
PCLO.V
PharmaCielo
2 months ago
PCLO.V
PharmaCielo
3 months ago
PCLO.V
PharmaCielo
4 months ago
PCLO.V
PharmaCielo
4 months ago
PCLO.V
PharmaCielo
4 months ago
PCLO.V
PharmaCielo
5 months ago
PCLO.V
PharmaCielo
6 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
9 months ago
PCLO.V
PharmaCielo
9 months ago
PCLO.V
PharmaCielo
10 months ago
PCLO.V
PharmaCielo
10 months ago
PCLO.V
PharmaCielo
11 months ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
No. of Analysts1111
Avg. Estimate0.020.05-0.140.37
Low Estimate0.020.05-0.140.37
High Estimate0.020.05-0.140.37
Year Ago EPS-0.13-0.07-0.33-0.14
Revenue EstimateCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
No. of Analysts1122
Avg. Estimate2.05M6.49M6.03M64.93M
Low Estimate2.05M6.49M3.82M52.87M
High Estimate2.05M6.49M8.25M76.99M
Year Ago Sales647k515k787k6.03M
Sales Growth (year/est)216.80%1,160.20%666.20%976.80%
Earnings History2019-12-302020-03-302020-06-292020-09-29
EPS Est.-0.04-0.1-0.040.01
EPS Actual-0.13-0.07-0.07-0.05
Difference-0.090.03-0.03-0.06
Surprise %-225.00%30.00%-75.00%-600.00%
EPS TrendCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
Current Estimate0.020.05-0.140.37
7 Days Ago0.020.05-0.140.37
30 Days Ago0.020.05-0.140.37
60 Days Ago0.020.05-0.140.37
90 Days Ago0.020.05-0.140.37
EPS RevisionsCurrent Qtr. (Dec 2020)Next Qtr. (Mar 2021)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesPCLO.VIndustrySector(s)S&P 500
Current Qtr.115.40%N/AN/AN/A
Next Qtr.171.40%N/AN/AN/A
Current Year57.60%N/AN/AN/A
Next Year364.30%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
2.32%% of Shares Held by All Insider
5.83%% of Shares Held by Institutions
5.96%% of Float Held by Institutions
5Number of Institutions Holding Shares

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Global X Fds-The Global X Cannabis ETF2,574,534Feb. 27, 20211.86%6,230,372
Wasatch Microcap Fund1,977,269Dec. 30, 20201.43%4,112,719
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF170,000Mar. 30, 20210.12%311,100
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by PharmaCielo Ltd.


PharmaCielo Announces Closing of Overnight Marketed Equity Offering for Gross Proceeds of $13.5 Million

PharmaCielo Announces Closing of Overnight Marketed Equity Offering for Gross Proceeds of $13.5 Million

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ All figures are in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, April 7, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and produc... Read More...
PharmaCielo Provides Corporate Update

PharmaCielo Provides Corporate Update

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ All figures are in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, March 31, 2021 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and produ... Read More...
PharmaCielo Ltd. Announces Upsize and Pricing of Overnight Marketed Equity Offering

PharmaCielo Ltd. Announces Upsize and Pricing of Overnight Marketed Equity Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO and RIONEGRO, Colombia, March 4, 2021 - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), is pleased to announce the pricing of its previously announced overnight marketed offering (the "Offering") of co... Read More...
PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate

PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate

Shipped to existing Customer with operations in the U.K. and the E.U. THC-free broad-spectrum distillate from a single cultivar is a superior core formulation for nutraceutical and cosmetic formulations PharmaCielo is among the few global producers that deliver broad-spectrum formulations produced from specially selected, developed and... Read More...
PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

TORONTO, Dec. 18, 2020 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. today announced that the company has expanded investor relations support capacity with the appointment of Caroline Lenardon to provi... Read More...
PharmaCielo Enters Strategic Alliance to Provide Pre-Tested and Insured Product to Customers in the U.S. Market

PharmaCielo Enters Strategic Alliance to Provide Pre-Tested and Insured Product to Customers in the U.S. Market

Alliance with AssuredTrans Inc. will enable PharmaCielo to provide up-front independent laboratory analysis and insurance of its recently expanded product portfolio to potential customers in the U.S., beginning in 2021 Former congressman notes alliance enables U.S. customers to have confidence in the purity and quality of PharmaCielo's ... Read More...
PharmaCielo Receives Approximately CDN$3.0 Million in Non-Dilutive Funding from Colombian State-Owned Banco Agrario

PharmaCielo Receives Approximately CDN$3.0 Million in Non-Dilutive Funding from Colombian State-Owned Banco Agrario

Loan of COP$8.5 billion (approximately CDN$3.0 million1) has an 84-month term, 10.14% coupon and revolving component with no equity dilution This loan together with the proceeds of the recent CDN$10mm equity financing put the company in a well-capitalized position to execute on its growing sales pipeline. TORONTO and RIONEGRO, Colombia... Read More...
PharmaCielo Welcomes Landmark United Nations Decision to Remove Cannabis from Narcotic Drugs List

PharmaCielo Welcomes Landmark United Nations Decision to Remove Cannabis from Narcotic Drugs List

TORONTO, Dec. 3, 2020 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF) the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Holdings"), commends the United Nations Commission on Narcotic Drugs (CND) for its historic decision... Read More...
PharmaCielo Announces Grant of Stock Options

PharmaCielo Announces Grant of Stock Options

TORONTO and RIONEGRO, Colombia, Dec. 2, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Holdings"), today announced that the board of directors of the Company approved... Read More...
PharmaCielo Announces Financial Results for the Third Quarter Ended September 30, 2020

PharmaCielo Announces Financial Results for the Third Quarter Ended September 30, 2020

Effective December 1, Henning von Koss has been named CEO of PharmaCielo, replacing departing CEO David Attard. Successful achievement of Q3 operational milestones: Processing and Extraction Centre ("PEC") construction completed ‚Äď one of largest current extraction footprints1 globally; expanded product portfolio launched. Plan to initi... Read More...
PharmaCielo Ltd. Announces New Leadership

PharmaCielo Ltd. Announces New Leadership

David Attard and Board of Directors reach mutual agreement under which David will step down as Chief Executive Officer and PharmaCielo board member, effective December 1st, 2020. Henning von Koss, currently President and a member of PharmaCielo's Board of Directors, formerly with Bayer and 30-year career as senior executive with operati... Read More...
PharmaCielo Achieves Good Agricultural and Collection Practices (GACP) Designation

PharmaCielo Achieves Good Agricultural and Collection Practices (GACP) Designation

Designation brings PharmaCielo a step closer to EU-GMP compliance; supports continued expansion of medicinal-grade extract exports GACP certification is based on WHO guidelines for quality assurance and control of herbal medicines TORONTO and RIONEGRO, Colombia, Nov. 25, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: P... Read More...
PharmaCielo Enters U.K. Market with 500kg Initial Shipment to Established Manufacturer and Distributor - Reaches 2021 Agreement

PharmaCielo Enters U.K. Market with 500kg Initial Shipment to Established Manufacturer and Distributor – Reaches 2021 Agreement

Including Initial Shipment, PharmaCielo will deliver total 1,000 kg of product to Customer ‚Äď with revenue and cash flow reflected in 2020; interim 2021 sales agreement reached for continued Q1 volume and revenue.Relationship adds U.K. and additional E.U. exposure to PharmaCielo's current commercial relationships in the U.S., Germany, Swit... Read More...
PharmaCielo to Hold Conference Call to Review Third Quarter 2020 Financial Results

PharmaCielo to Hold Conference Call to Review Third Quarter 2020 Financial Results

TORONTO and RIONEGRO, Colombia, Nov. 12, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it will host a conference call on Monday, November 30th... Read More...
PharmaCielo Ltd. Expands Board Depth and Expertise with Appointment of Marc Lustig as Lead Director and Strengthens Capital Position with Private Placement Offering

PharmaCielo Ltd. Expands Board Depth and Expertise with Appointment of Marc Lustig as Lead Director and Strengthens Capital Position with Private Placement Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Nov. 2, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) is pleased to announce that Marc Lustig, the highly successful cannabis industry leader with expertise in both capital markets and health ... Read More...
PharmaCielo to Participate in Cantor Fitzgerald Latin America Cannabis Seminar

PharmaCielo to Participate in Cantor Fitzgerald Latin America Cannabis Seminar

TORONTO, Oct. 23, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that it will be participating in Cantor Fitzgerald's Latin America Cannabis Se... Read More...
PharmaCielo Declared 'Project of National Strategic Interest' by Government of Colombia

PharmaCielo Declared ‘Project of National Strategic Interest’ by Government of Colombia

TORONTO and RIONEGRO, Colombia, Sept. 22, 2020 - PharmaCielo Ltd. ("PharmaCielo") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is very pleased to announce that the Colombian Intersectoral Commission for Strategic P... Read More...
PharmaCielo Expands Portfolio of Cannabis Extracts to Meet Global B2B Medical-Grade Market Demand

PharmaCielo Expands Portfolio of Cannabis Extracts to Meet Global B2B Medical-Grade Market Demand

New offerings allow PharmaCielo to respond to market demand with expanded product rangeExtracts derived from proprietary cultivars and produced internally at 30,000+ sq. ft. processing and extraction facilityIndependent analytical verification of unique medicinal profile and high qualityCurrent inventories support immediate new product sa... Read More...
PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2020 and Provides Operational Update

PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2020 and Provides Operational Update

Revenue continues to accelerate. The Company generated $1.2 million in revenue during Q2-2020, reaching $1.7 Million YTD 2020 compared to $786,901 in its full 2019 fiscal year.Recent increase in active cultivation footprint readies PharmaCielo to process and deliver more extracted product during the second half of 2020 and into 2021.Produ... Read More...
PharmaCielo to Hold Conference Call to Review Second Quarter 2020 Financial Results

PharmaCielo to Hold Conference Call to Review Second Quarter 2020 Financial Results

TORONTO and RIONEGRO, Colombia, Aug. 18, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it will host a conference call on Monday, August 31st, ... Read More...
PharmaCielo Increases Cannabis Cultivation Through External Contractor to Meet Market Demand for Medicinal Extracts

PharmaCielo Increases Cannabis Cultivation Through External Contractor to Meet Market Demand for Medicinal Extracts

Additional area under active cultivation expands PharmaCielo's immediate footprint by 32 percent to 1.6 million square feet with further expansion pending grower license approvalCompany activates first external cultivation contract with local growerIncreased volumes contribute to expanded 360 tonne biomass processing capacity of the Compa... Read More...
PharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export

PharmaCielo Receives Colombian Government Authorization for 10 Tonnes of High-THC Cultivation and Extract Production for Export

Enables PharmaCielo to produce and deliver psychoactive extracts as part of the three-year extracts agreement the Company announced in January of this year, intended for the German marketEnhances product development flexibility and will accelerate PharmaCielo's strategic priority to expand beyond CBD oils and isolates to meet market deman... Read More...
PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2020 and Provides Operational Update

PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2020 and Provides Operational Update

PharmaCielo generated $514,409 in revenue during Q1-2020, compared to revenue of $786,901 in its full 2019 fiscal year.Pro forma cash and cash equivalents of $12.7 million 1.Processing equipment is now on-site in Rionegro; the Company expects to be in a position to begin accepting broad spectrum commercial pre-orders by the end of Q2. All... Read More...
PharmaCielo Welcomes Dr. Claudia Jiménez to Board of Directors

PharmaCielo Welcomes Dr. Claudia Jiménez to Board of Directors

TORONTO , May 12, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) is pleased to welcome Dr. Claudia Jiménez (Ph.D.) to its board of directors. As a board member, Dr. Jiménez will also serve on the Company's Audit, Nominating and Corporate Governance committees. Dr. Jiménez's appointment is effective Jun... Read More...
PharmaCielo Adds Experienced Senior Leader to Executive Team

PharmaCielo Adds Experienced Senior Leader to Executive Team

¬†Henning von Koss ‚Äď a proven 30-year veteran of the global pharmaceutical, chemical and healthcare industries ‚Äď named President to focus on scaling international operations TORONTO, May 4, 2020 - PharmaCielo¬†Ltd. ("PharmaCielo" or¬†the¬†"Company") (TSXV: PCLO, OTCQX: PCLOF), is pleased to announce¬†the appointment of Mr. Henning von Koss to ... Read More...
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2019

PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2019

PharmaCielo generated a record $657,000 in revenue during Q4. Generated revenue of $786,901 in fiscal 2019. $13.7 million in cash and cash equivalents at December 31, 2019 ; Subsequent to the end of the quarter, the Company closed a private placement financing for gross proceeds of approximately $8 million .All figures are in Canadian do... Read More...
PharmaCielo Provides Details for Fourth Quarter and Year-End 2019 Results Conference Call

PharmaCielo Provides Details for Fourth Quarter and Year-End 2019 Results Conference Call

TORONTO , April 29, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX:PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., advised today that it will be holding its fourth quarter and fiscal 2019 financial results conf... Read More...
PharmaCielo Ltd. Announces Closing of Previously Announced $8 Million Private Placement Financing

PharmaCielo Ltd. Announces Closing of Previously Announced $8 Million Private Placement Financing

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, April 15, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) announced today that it has closed its previously announced "best efforts" private placement financing of 12,428,002 special warrants of... Read More...
PharmaCielo Ltd. Prices $8 Million Offering; Closing Scheduled for April 14

PharmaCielo Ltd. Prices $8 Million Offering; Closing Scheduled for April 14

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, April 6, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) announced today that further to its April 1 release, it has received subscriptions and subscription commitments in excess of CAD$8 millio... Read More...
PharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market

PharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market

PharmaCielo will sell a broad range of extracts ‚Äď including both CBD- and THC-dominant profiles ‚Äď to XPhyto Therapeutics Corp., for German market distribution Three-year agreement signed, covering a minimum delivery target of 30,000 kg, beginning mid-2020 GAP and ISO 9001:2015 Certifications Provide Key Quality Confirmation to Custo... Read More...
PharmaCielo Signs Pan-European Distribution Agreement for CBD Isolate and Broad-Spectrum CBD Oil

PharmaCielo Signs Pan-European Distribution Agreement for CBD Isolate and Broad-Spectrum CBD Oil

Company signs a three-year performance-based agreement with CBD Export GlobalDistribution channel covers the entire EU-zone as well as Switzerland and LichtensteinShipments to commence in 2020 with increasing volumes during duration of AgreementTORONTO and RIONEGRO, Colombia , Jan. 24, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Compan... Read More...
PharmaCielo to Hold Conference Call to Review Third Quarter 2019 Financial Results

PharmaCielo to Hold Conference Call to Review Third Quarter 2019 Financial Results

TORONTO , Nov. 25, 2019 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announces today that it will host a conference call on Monday, November 25 th, 2019, at 5:00 p.... Read More...
PharmaCielo Announces Financial Results for the Three and Nine Months Ended September 30, 2019

PharmaCielo Announces Financial Results for the Three and Nine Months Ended September 30, 2019

"All-in" cost to produce dried cannabis of $0.04i¬†per gram in Q3 ‚Äď 20% better than targeted. Net loss significantly reduced to $3.8 million compared to $10.7 million in Q2-2019. Well capitalized with cash and short-term investments of $20.7 million as of September 30, 2019. Initiating commercial sales ‚Äď Completed sales negotiation... Read More...
Coming Soon.

Delayed data (1h)
NameAgePositionAppointed
Simon Anthony Christopher Langelier
Chairman of the Board
--Chairman of the Board--
David Attard
Chief Executive Officer, Director
--Chief Executive Officer, Director--
Scott Laitinen
Chief Financial Officer
--Chief Financial Officer--
David Gordon
Chief Corporate Officer
--Chief Corporate Officer--
Delon Human
Global Head, Health and Innovation
--Global Head, Health and Innovation--
Douglas H. Bache
Director
--Director--
Matteo Lorenzo Pellegrini
Director
--Director--
Carlos Manuel Uribe
Director
--Director--
Henning von Koss
Director
--Director--


Share this page